C4 Therapeutics (CCCC)
Market Price (2/20/2026): $2.09 | Market Cap: $151.7 MilSector: Health Care | Industry: Biotechnology
C4 Therapeutics (CCCC)
Market Price (2/20/2026): $2.09Market Cap: $151.7 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -85% | Weak multi-year price returns2Y Excs Rtn is -108%, 3Y Excs Rtn is -128% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -119 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -395% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -11%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.0%, Rev Chg QQuarterly Revenue Change % is -27% | |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 77% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -314%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -315% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -82% | ||
| High stock price volatilityVol 12M is 101% | ||
| Key risksCCCC key risks include [1] the early development stage of its lead candidates, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -85% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -108%, 3Y Excs Rtn is -128% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -119 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -395% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -11%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.0%, Rev Chg QQuarterly Revenue Change % is -27% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 77% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -314%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -315% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -82% |
| High stock price volatilityVol 12M is 101% |
| Key risksCCCC key risks include [1] the early development stage of its lead candidates, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Dilution from Underwritten Offering.
C4 Therapeutics priced a $125 million underwritten offering around October 17, 2025, which included shares of common stock and pre-funded warrants. Investor concerns over the potential dilution from this offering continued to pressure sentiment in the subsequent months, despite the company's intention to use the proceeds to fund clinical trials and extend its cash runway through year-end 2028.
2. Analyst Downgrades and Reduced Price Targets.
Analyst sentiment shifted negatively, with Barclays reducing its price target on C4 Therapeutics from $10.00 to $5.00 in a December 17, 2025 report, while maintaining an "overweight" rating. Additionally, Weiss Ratings reissued a "sell (d-)" rating on the stock in a January 21, 2026 research report.
Show more
Stock Movement Drivers
Fundamental Drivers
The -18.8% change in CCCC stock from 10/31/2025 to 2/19/2026 was primarily driven by a -12.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 2192026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.61 | 2.12 | -18.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 34 | 30 | -12.1% |
| P/S Multiple | 5.4 | 5.1 | -5.6% |
| Shares Outstanding (Mil) | 71 | 73 | -2.1% |
| Cumulative Contribution | -18.8% |
Market Drivers
10/31/2025 to 2/19/2026| Return | Correlation | |
|---|---|---|
| CCCC | -18.8% | |
| Market (SPY) | 0.4% | 30.5% |
| Sector (XLV) | 9.0% | 22.1% |
Fundamental Drivers
The 3.4% change in CCCC stock from 7/31/2025 to 2/19/2026 was primarily driven by a 40.0% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2192026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.05 | 2.12 | 3.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 40 | 30 | -24.3% |
| P/S Multiple | 3.6 | 5.1 | 40.0% |
| Shares Outstanding (Mil) | 71 | 73 | -2.4% |
| Cumulative Contribution | 3.4% |
Market Drivers
7/31/2025 to 2/19/2026| Return | Correlation | |
|---|---|---|
| CCCC | 3.4% | |
| Market (SPY) | 8.6% | 17.8% |
| Sector (XLV) | 21.1% | 5.3% |
Fundamental Drivers
The -38.9% change in CCCC stock from 1/31/2025 to 2/19/2026 was primarily driven by a -28.8% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2192026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.47 | 2.12 | -38.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 34 | 30 | -10.6% |
| P/S Multiple | 7.2 | 5.1 | -28.8% |
| Shares Outstanding (Mil) | 70 | 73 | -4.0% |
| Cumulative Contribution | -38.9% |
Market Drivers
1/31/2025 to 2/19/2026| Return | Correlation | |
|---|---|---|
| CCCC | -38.9% | |
| Market (SPY) | 14.7% | 29.1% |
| Sector (XLV) | 8.5% | 23.9% |
Fundamental Drivers
The -72.8% change in CCCC stock from 1/31/2023 to 2/19/2026 was primarily driven by a -37.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312023 | 2192026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.79 | 2.12 | -72.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 48 | 30 | -37.7% |
| P/S Multiple | 7.9 | 5.1 | -35.2% |
| Shares Outstanding (Mil) | 49 | 73 | -32.6% |
| Cumulative Contribution | -72.8% |
Market Drivers
1/31/2023 to 2/19/2026| Return | Correlation | |
|---|---|---|
| CCCC | -72.8% | |
| Market (SPY) | 74.7% | 23.5% |
| Sector (XLV) | 23.4% | 22.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CCCC Return | -3% | -82% | -4% | -36% | -47% | 0% | -94% |
| Peers Return | -1% | -63% | -2% | 17% | 39% | 2% | -40% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 83% |
Monthly Win Rates [3] | |||||||
| CCCC Win Rate | 50% | 42% | 42% | 25% | 50% | 50% | |
| Peers Win Rate | 54% | 35% | 40% | 50% | 53% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| CCCC Max Drawdown | -11% | -84% | -80% | -36% | -69% | -10% | |
| Peers Max Drawdown | -39% | -71% | -59% | -38% | -50% | -11% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ARVN, KYMR, NRIX, GLUE, FHTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/19/2026 (YTD)
How Low Can It Go
| Event | CCCC | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -97.7% | -25.4% |
| % Gain to Breakeven | 4179.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -19.1% | -33.9% |
| % Gain to Breakeven | 23.6% | 51.3% |
| Time to Breakeven | 12 days | 148 days |
Compare to ARVN, KYMR, NRIX, GLUE, FHTX
In The Past
C4 Therapeutics's stock fell -97.7% during the 2022 Inflation Shock from a high on 9/23/2021. A -97.7% loss requires a 4179.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About C4 Therapeutics (CCCC)
AI Analysis | Feedback
```html- Moderna, but for cancer drugs that work by destroying disease-causing proteins.
- Genentech or Bristol Myers Squibb, but specializing in a revolutionary new type of cancer drug that degrades specific proteins.
- Vertex Pharmaceuticals, but building a platform for a new class of drugs to eliminate cancer-causing proteins.
AI Analysis | Feedback
- CFT7455: An orally available IKZF1/3 degrader currently in clinical development for the treatment of multiple myeloma and non-Hodgkin lymphoma.
- CFT8634: An orally available BRD9 degrader currently in clinical development for the treatment of synovial sarcoma and other solid tumors.
- CFT1946: An orally available BRAF V600E degrader currently in clinical development for the treatment of melanoma and other BRAF V600E-mutant cancers.
AI Analysis | Feedback
C4 Therapeutics (CCCC) is a clinical-stage biopharmaceutical company that develops novel targeted protein degraders for the treatment of cancer and other diseases. As such, it does not sell products directly to individuals. Instead, its "customers" are primarily other pharmaceutical companies with whom it forms strategic collaborations and licensing agreements for drug discovery, development, and commercialization. The major customer companies (collaborators) for C4 Therapeutics are:-
Roche / Genentech
(Symbol: RHHBY)
C4 Therapeutics entered into a multi-target strategic collaboration with Roche and Genentech in March 2021 for the discovery and development of targeted protein degraders for oncology and other diseases.
-
Merck KGaA, Darmstadt, Germany
(Symbol: MKKGY)
C4 Therapeutics established a collaboration with Merck KGaA in 2016 (later expanded) for the discovery and development of novel targeted protein degraders in oncology.
AI Analysis | Feedback
nullAI Analysis | Feedback
Andrew Hirsch, President & Chief Executive Officer
Mr. Hirsch has over 20 years of experience in strategic and operating roles, including more than 15 years in the biotechnology industry. Before joining C4 Therapeutics, he served as Chief Financial Officer and head of corporate development at Agios Pharmaceuticals. Mr. Hirsch was previously the President and Chief Executive Officer of BIND Therapeutics and the Chief Financial Officer at Avila Therapeutics, which was acquired by Celgene. He also spent nearly 10 years at Biogen, where his roles included Vice President of Corporate Strategy and M&A.
Kendra Adams, Chief Financial Officer & Treasurer
Ms. Adams was appointed Chief Financial Officer in September 2023, having joined C4 Therapeutics in November 2020 as Senior Vice President, Investor Relations & Corporate Communications. She brings over 25 years of experience in financial, operational, and strategic planning, with nearly two decades in the biotechnology sector. Her prior roles include investor relations leadership positions at Agios Pharmaceuticals, ARIAD Pharmaceuticals, and Amgen. Ms. Adams began her career at General Electric in their Financial Management Program and later led consulting teams at KPMG LLP.
Jolie Siegel, Chief Legal Officer & Secretary
Ms. Siegel serves as the Chief Legal Officer and Secretary for C4 Therapeutics.
Kelly Schick, Chief People Officer
Ms. Schick holds the position of Chief People Officer at C4 Therapeutics.
Scott Boyle, Chief Business Officer
Dr. Boyle serves as the Chief Business Officer for C4 Therapeutics.
AI Analysis | Feedback
C4 Therapeutics (CCCC) faces several key risks inherent to its position as a clinical-stage biopharmaceutical company.-
Clinical Development and Regulatory Approval Risks
As a clinical-stage biopharmaceutical company, C4 Therapeutics' success is heavily contingent on the successful development, regulatory approval, and eventual commercialization of its product candidates. There are significant uncertainties and lengthy timelines associated with clinical trials, and early-stage trial results may not be indicative of success in later stages. The company's lead candidates, such as cemsidomide and CFT1946, are still in early phases of clinical development, and there have been noted safety concerns, including a high rate of higher-grade adverse events in some early trials, which could lead to unacceptable toxicity findings in the future. The approval process for novel therapies can be expensive and time-consuming, and there is no guarantee that any of C4 Therapeutics' product candidates will receive regulatory approval. -
Financial Risks: Cash Burn and Need for Additional Capital
C4 Therapeutics is a company with a history of substantial losses and no revenue from product sales, reflecting its clinical-stage nature. The company incurs significant financial risks due to its considerable cash burn, meaning it spends a large amount of cash to fund its research, development, and operational activities. While C4 Therapeutics has reported sufficient cash and marketable securities to fund operations into 2027, it anticipates continued losses and significant expenses as it advances its product pipeline. The company relies heavily on raising additional capital through equity offerings, debt offerings, or collaborations, which could result in dilution for existing stockholders or unfavorable financing terms. -
Competitive Risks
C4 Therapeutics operates in a highly competitive biopharmaceutical industry. The company faces competition from other pharmaceutical and biotechnology companies that are developing or may develop similar targeted protein degradation therapies or other treatments for the diseases C4 Therapeutics is targeting. This competition could impact the company's ability to successfully develop, commercialize, and achieve market acceptance for its product candidates, potentially affecting its market position and financial performance.
AI Analysis | Feedback
The primary emerging threat is the intense and rapidly advancing competition within the targeted protein degradation (TPD) therapeutic space. Numerous well-funded companies, including larger pharmaceutical firms like Arvinas, Kymera Therapeutics, Nurix Therapeutics, Bristol Myers Squibb, and others, are aggressively developing TPD candidates, often targeting similar high-value oncology indications as C4 Therapeutics. Should a competitor achieve superior clinical trial results or an earlier market approval for a TPD program, it could significantly diminish the market opportunity, differentiation, and investment appeal for C4 Therapeutics' own pipeline candidates in this crowded and nascent field.
AI Analysis | Feedback
C4 Therapeutics (CCCC) is a clinical-stage biopharmaceutical company focused on developing targeted protein degraders for various diseases, primarily in oncology. The addressable markets for their main product candidates are detailed below:
-
Cemsidomide (targeting IKZF1/3 degradation)
- Multiple Myeloma (MM): The global multiple myeloma market size was valued at approximately USD 27.58 billion in 2024, with projections to reach USD 44.19 billion by 2032. North America accounted for 58.30% of this market in 2024. Other sources estimate the global market at USD 27.75 billion in 2024, growing to approximately USD 49.89 billion by 2034, or USD 28.42 billion in 2024, projected to reach USD 47.04 billion by 2032.
- Non-Hodgkin Lymphoma (NHL): The non-Hodgkin lymphoma market across the top 7 markets (U.S., EU4, U.K., and Japan) reached USD 4.2 billion in 2024 and is expected to grow to USD 7.8 billion by 2035. The global non-Hodgkin lymphoma therapeutics market was valued at USD 9.5 billion in 2023 and is estimated to grow to USD 16.64 billion by 2032. The U.S. alone accounted for USD 3.9 billion of the North American non-Hodgkin lymphoma therapeutics market in 2023.
-
CFT1946 (targeting BRAF V600X mutations)
- BRAF V600X Solid Tumors (including Melanoma): The global drugs for melanoma market surpassed USD 10.87 billion in 2024 and is expected to reach USD 26.15 billion by 2032. More specifically, the global BRAF kinase inhibitors market, which targets mutations like BRAF V600E, was valued at USD 315 million in 2024 and is estimated to reach USD 673 million by 2033.
-
CFT8919 (targeting EGFR L858R mutation in Non-Small Cell Lung Cancer)
- Null
-
Discovery Programs (e.g., in collaboration with Biogen for neurological conditions like Alzheimer's and Parkinson's disease)
- Null
AI Analysis | Feedback
C4 Therapeutics (NASDAQ: CCCC) is expected to drive future revenue growth over the next 2-3 years through the advancement of its clinical pipeline, the achievement of milestones from strategic collaborations, and the continued expansion of its targeted protein degradation (TPD) platform.
-
Advancement and Potential Commercialization of Clinical Pipeline: A primary driver of future revenue for C4 Therapeutics is the progression and potential commercialization of its lead drug candidates. The company is focused on advancing cemsidomide, particularly with plans to initiate a registrational Phase 2 MOMENTUM trial in combination with dexamethasone for multiple myeloma in early 2026, which holds potential for accelerated approval. Additionally, a Phase 1b trial for cemsidomide in combination with Pfizer's elranatamab is slated for Q2 2026. The company also expects progress from CFT1946 for BRAF V600X solid tumors, with data in melanoma and colorectal cancer anticipated in the second half of 2025, and CFT8919, which is progressing through Phase 1 dose escalation in Greater China in partnership with Betta Pharmaceuticals.
-
Milestone Payments and Royalties from Strategic Collaborations: C4 Therapeutics generates significant revenue through its strategic collaborations. The company has ongoing partnerships with major pharmaceutical companies, including a new collaboration with Pfizer for cemsidomide and existing agreements with MKDG, Betta Pharma, Merck, and Roche. These collaborations often include upfront payments, milestone payments based on development and regulatory achievements, and potential future royalties on product sales. For instance, the Merck collaboration could yield up to approximately $600 million in milestone payments, along with tiered royalties on future sales. Achieving preclinical and clinical milestones with these partners is a crucial source of revenue as their programs advance.
-
Expansion of Targeted Protein Degradation (TPD) Pipeline: C4 Therapeutics leverages its proprietary TORPEDO® platform to discover and develop new small-molecule medicines that utilize targeted protein degradation. The company plans to continue using this platform to develop orally bioavailable degraders for various oncology and non-oncology targets, both for its internal research programs and collaboration initiatives. The success of the TORPEDO® platform in identifying and advancing novel drug candidates will underpin the company's long-term growth by continuously replenishing its pipeline with high-potential therapies, thereby creating future licensing and commercialization opportunities.
AI Analysis | Feedback
Share Issuance
- C4 Therapeutics completed an underwritten offering in October 2025, raising $125.0 million in gross proceeds, with potential for an additional $225.0 million if outstanding warrants are exercised.
- Approximately $82.3 million in net proceeds were generated from its "at-the-market" (ATM) program, which allowed for the sale of up to $200.0 million in common stock, through December 31, 2024.
- In January 2024, C4 Therapeutics completed a $25.0 million equity investment from a subsidiary of Betta Pharmaceuticals.
Inbound Investments
- In March 2024, C4 Therapeutics entered into a strategic discovery research collaboration with Merck KGaA, Darmstadt, Germany, receiving an upfront payment of $16.0 million and potential for up to approximately $740.0 million in milestone payments.
- A license and research collaboration with Merck was established in December 2023 for degrader antibody conjugates, which included a $10.0 million upfront payment received in January 2024 and eligibility for approximately $600.0 million in milestone payments.
- C4 Therapeutics received an $8.0 million milestone payment from Biogen in the second quarter of 2024 after Biogen accepted delivery of a development candidate.
Outbound Investments
- C4 Therapeutics has not made any investments or acquisitions.
Capital Expenditures
- C4 Therapeutics expects its existing cash, cash equivalents, and marketable securities to be sufficient to fund planned operating expenses and capital expenditures into 2027.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| C4 Therapeutics Earnings Notes | 12/16/2025 | |
| With C4 Therapeutics Stock Sliding, Have You Assessed The Risk? | 10/17/2025 | |
| Day 8 of Loss Streak for C4 Therapeutics Stock with -39% Return (vs. -39% YTD) [9/25/2025] | 09/26/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CCCC.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -14.6% | -14.6% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 19.5% | 19.5% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 9.7% | 9.7% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -39.4% | -39.4% | -40.1% |
| 01022026 | CORT | Corcept Therapeutics | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 4.6% | 4.6% | -9.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 14.11 |
| Mkt Cap | 1.2 |
| Rev LTM | 64 |
| Op Inc LTM | -111 |
| FCF LTM | -163 |
| FCF 3Y Avg | -141 |
| CFO LTM | -161 |
| CFO 3Y Avg | -136 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 25.0% |
| Rev Chg 3Y Avg | 27.0% |
| Rev Chg Q | -12.0% |
| QoQ Delta Rev Chg LTM | -0.9% |
| Op Mgn LTM | -346.5% |
| Op Mgn 3Y Avg | -367.5% |
| QoQ Delta Op Mgn LTM | -12.3% |
| CFO/Rev LTM | -305.4% |
| CFO/Rev 3Y Avg | -328.2% |
| FCF/Rev LTM | -314.4% |
| FCF/Rev 3Y Avg | -355.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.2 |
| P/S | 11.8 |
| P/EBIT | -4.8 |
| P/E | -5.4 |
| P/CFO | -3.5 |
| Total Yield | -12.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -19.2% |
| D/E | 0.0 |
| Net D/E | -0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 0.3% |
| 3M Rtn | 20.0% |
| 6M Rtn | 67.0% |
| 12M Rtn | -4.8% |
| 3Y Rtn | 29.4% |
| 1M Excs Rtn | -0.6% |
| 3M Excs Rtn | 19.5% |
| 6M Excs Rtn | 60.3% |
| 12M Excs Rtn | -15.8% |
| 3Y Excs Rtn | -51.5% |
Price Behavior
| Market Price | $2.12 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 10/02/2020 | |
| Distance from 52W High | -40.6% | |
| 50 Days | 200 Days | |
| DMA Price | $2.09 | $2.15 |
| DMA Trend | up | down |
| Distance from DMA | 1.4% | -1.4% |
| 3M | 1YR | |
| Volatility | 77.4% | 101.5% |
| Downside Capture | 250.98 | 222.28 |
| Upside Capture | 119.65 | 160.03 |
| Correlation (SPY) | 33.7% | 30.0% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.07 | 1.88 | 1.95 | 1.69 | 1.53 | 2.05 |
| Up Beta | -0.17 | 0.99 | 1.05 | 0.35 | 0.97 | 1.45 |
| Down Beta | 0.83 | 2.12 | 1.90 | 3.12 | 1.77 | 2.01 |
| Up Capture | -63% | 11% | 110% | 108% | 177% | 835% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 8 | 15 | 26 | 52 | 104 | 316 |
| Down Capture | -80% | 342% | 274% | 169% | 154% | 113% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 11 | 25 | 32 | 68 | 137 | 416 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CCCC | |
|---|---|---|---|---|
| CCCC | -28.7% | 101.5% | 0.11 | - |
| Sector ETF (XLV) | 10.3% | 17.3% | 0.41 | 23.7% |
| Equity (SPY) | 13.0% | 19.4% | 0.51 | 29.6% |
| Gold (GLD) | 71.2% | 25.5% | 2.08 | 6.7% |
| Commodities (DBC) | 7.3% | 16.9% | 0.25 | 14.8% |
| Real Estate (VNQ) | 6.4% | 16.7% | 0.20 | 23.2% |
| Bitcoin (BTCUSD) | -30.2% | 44.9% | -0.66 | 26.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CCCC | |
|---|---|---|---|---|
| CCCC | -45.9% | 115.8% | -0.08 | - |
| Sector ETF (XLV) | 7.8% | 14.5% | 0.36 | 24.0% |
| Equity (SPY) | 13.4% | 17.0% | 0.62 | 28.5% |
| Gold (GLD) | 22.0% | 17.1% | 1.05 | 7.6% |
| Commodities (DBC) | 11.0% | 19.0% | 0.47 | 3.7% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 27.9% |
| Bitcoin (BTCUSD) | 6.9% | 57.1% | 0.34 | 16.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CCCC | |
|---|---|---|---|---|
| CCCC | -22.0% | 113.6% | 0.04 | - |
| Sector ETF (XLV) | 11.1% | 16.5% | 0.56 | 22.9% |
| Equity (SPY) | 15.8% | 17.9% | 0.76 | 28.0% |
| Gold (GLD) | 15.0% | 15.6% | 0.80 | 6.5% |
| Commodities (DBC) | 8.7% | 17.6% | 0.41 | 3.9% |
| Real Estate (VNQ) | 6.8% | 20.7% | 0.29 | 27.3% |
| Bitcoin (BTCUSD) | 67.7% | 66.7% | 1.07 | 15.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | 0.4% | 4.6% | 7.2% |
| 8/7/2025 | 31.6% | 18.9% | 38.8% |
| 2/27/2025 | -1.9% | -8.3% | -30.6% |
| 10/31/2024 | -3.6% | 8.0% | -17.7% |
| 5/8/2024 | -5.0% | -11.6% | -30.5% |
| 2/22/2024 | 21.4% | 51.0% | 20.1% |
| 11/1/2023 | -11.4% | 25.5% | 9.4% |
| 8/8/2023 | -0.3% | -4.0% | -32.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 10 | 8 |
| # Negative | 8 | 8 | 10 |
| Median Positive | 7.3% | 11.5% | 20.7% |
| Median Negative | -3.8% | -10.2% | -25.2% |
| Max Positive | 31.6% | 51.0% | 38.8% |
| Max Negative | -11.4% | -29.9% | -37.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/22/2024 | 10-K |
| 09/30/2023 | 11/01/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/23/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 02/24/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Boyle, Scott N | Chief Business Officer | Direct | Sell | 2182025 | 3.15 | 490 | 1,544 | 349,152 | Form |
| 2 | Boyle, Scott N | Chief Business Officer | Direct | Sell | 2182025 | 3.15 | 669 | 2,107 | 339,586 | Form |
| 3 | Reyno, Leonard | Chief Medical Officer | Direct | Sell | 1162026 | 2.22 | 10,000 | 22,200 | 347,168 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.